Associated Papers
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
40588514 (PubMed )
Supplement: 41416_2025_3098_MOESM1_ESM.pdf
ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
Vacarean-Trandafir IC et al.
Molecular Biology Reports, 2019
Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P et al.
Leukemia & Lymphoma, 2010
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Branford S et al.
Blood, 2003
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Branford S et al.
Blood, 2002
Select a paper to view details